Total Clarity Wealth Management’s Autolus Therapeutics AUTL Stock Holding History

Total Clarity Wealth Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,200	Closed	-$3K	–	269
2022 Q2	$3K	Buy	+1,200	New	+$3.65K	﹤0.01%	870
2022 Q1	–	Sell	-1,200	Closed	-$6K	–	262
2021 Q4	$6K	Sell	1,200 -3,000	-71%	-$18K	﹤0.01%	772
2021 Q3	$28K	Buy	+4,200	New	+$26.5K	0.01%	492
2021 Q2	–	Sell	-1,000	Closed	-$6K	–	229
2021 Q1	$6K	Buy	+1,000	New	+$7.4K	﹤0.01%	643

Other funds holding AUTL

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Total Clarity Wealth Management's AUTL Position: Q3 2022 in Review

Total Clarity Wealth Management sold out of Autolus Therapeutics (AUTL) in Q3 2022, closing a stake of 1,200 shares — an estimated $3K sold.

Total Clarity Wealth Management first reported a position in AUTL in Q1 2021 and held it in 4 quarters. The position peaked at $28K in Q3 2021. 66 funds tracked by Wall St. Rank hold AUTL as of Q3 2022.

Total Clarity Wealth Management reported no remaining Autolus Therapeutics position as of Q3 2022 after selling out during the quarter.
Total Clarity Wealth Management sold 1,200 Autolus Therapeutics shares in Q3 2022, an estimated $3K.
Total Clarity Wealth Management first reported a position in Autolus Therapeutics in Q1 2021 and held it in 4 quarters.
Total Clarity Wealth Management's Autolus Therapeutics position peaked at $28K in Q3 2021.
66 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2022.

Based on Total Clarity Wealth Management's 13F filing for Q3 2022, filed 4 Nov 2022.